Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
Invest New Drugs
; 33(6): 1280-91, 2015 Dec.
Article
em En
| MEDLINE
| ID: mdl-26423245
ABSTRACT
A vast majority of lymphomas and leukaemias are results of translocations. These translocations produce various genetic and epigenetic changes that lead to oncogenesis. This opens an opportunity to use a relatively new class of anti-cancer agents, inhibitors of histone deacetylases (HDACi) to target lymphoid malignancies. Surprisingly, the rational basis for treatment of lymphomas with HDACi is far from clear, although some positive results have been obtained. Here we analyze the effect of histone deacetylase (HDAC) inhibitors on lymphoid malignancies.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Epigênese Genética
/
Inibidores de Histona Desacetilases
/
Linfoma
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Invest New Drugs
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
França